UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2016

 

OR

 

¨    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 001-36445

 

NanoVibronix, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware   01-0801232
(State or other jurisdiction of incorporation
or organization)
  (I.R.S. Employer Identification Number)
     
525 Executive Boulevard    
Elmsford, New York   10523
(Address of principal executive office)   (Zip Code)

 

Registrant’s telephone number, including area code: (914) 233-3004

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x    No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant has been required to submit and post such files). Yes x     No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨    Accelerated filer ¨
       
Non-accelerated filer  (Do not check if a smaller reporting company)   ¨    Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

The number of shares outstanding of the registrant’s common stock, par value $0. 001 per share, as of November 14, 2016 was 2,632,710 shares.

 

 

 

 

TABLE OF CONTENTS

 

  Page
PART I. FINANCIAL INFORMATION  
   
Item 1. Financial Statements 4
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 13
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 19
     
Item 4. Controls and Procedures 19
     
PART II. OTHER INFORMATION  
     
Item 1. Legal Proceedings 19
     
Item 1A. Risk Factors 19
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20
     
Item 3. Defaults Upon Senior Securities 20
     
Item 4. Mine Safety Disclosures 20
     
Item 5. Other Information 20
     
Item 6. Exhibits 20
     
Signatures 21
     
Exhibits 22

 

 - 2 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

PART I – FINANCIAL INFORMATION

 

NANOVIBRONIX INC. AND ITS SUBSIDIARY

 

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF SEPTEMBER 30, 2016

 

U.S. DOLLARS IN THOUSANDS

 

UNAUDITED

  

INDEX

  

 

Page

   
Consolidated Balance Sheets 4 - 5
   
Consolidated Statements of Comprehensive loss 6
   
Statements of Changes in Shareholders' Equity (Deficiency) 7
   
Consolidated Statements of Cash Flows 8
   
Notes to Consolidated Financial Statements 9 - 12

 

 - 3 - 

 

 

Item 1. Financial Statements

 

CONSOLIDATED BALANCE SHEETS (unaudited)

U.S. dollars in thousands (except share and per share data)

 

   September 30,   December 31, 
   2016   2015 
   Unaudited   Audited 
         
ASSETS          
           
CURRENT ASSETS:          
Cash and cash equivalents  $532   $1,614 
Trade receivables   11    5 
Prepaid expenses and other accounts receivable   71    86 
Inventories   63    71 
           
Total current assets   677    1,776 
           
PROPERTY AND EQUIPMENT, NET   12    10 
           
SEVERANCE PAY FUND   235    197 
           
Total assets  $924   $1,983 

  

The accompanying notes are an integral part of the interim consolidated financial statements.

 

 - 4 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

CONSOLIDATED BALANCE SHEETS (unaudited)

U.S. dollars in thousands (except share and per share data)

 

   September 30,   December 31, 
   2016   2015 
   Unaudited   Audited 
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)          
           
CURRENT LIABILITIES:          
Accounts payable  $69   $58 
Other accounts payable   334    239 
           
Total current liabilities   403    297 
           
NON-CURRENT LIABILITIES:          
Warrants to purchase Common stock   1,887    1,696 
Accrued severance pay   237    199 
           
Total long-term liabilities   2,124    1,895 
           
COMMITMENTS AND CONTINGENT LIABILITIES          
           
STOCKHOLDERS' EQUITY (DEFICIENCY):          
Stock capital -          
Common stock of $ 0.001 par value - Authorized: 20,000,000 shares at September 30, 2016 and December 31, 2015; Issued and outstanding: 2,632,710 and 2,611,328 shares at September 30, 2016 and December 31, 2015, respectively.   2    2 
Series C Preferred stock of $ 0.001 par value - Authorized: 5,000,000 shares at September 30, 2016 and December 31, 2015; Issued and outstanding: 1,951,261 at September 30, 2016 and December 31, 2015, respectively   2    2 
Additional paid-in capital   19,838    19,521 
Accumulated deficit   (21,445)   (19,734)
           
Total stockholders' equity (deficiency)   (1,603)   (209)
           
Total liabilities and stockholders' equity (deficiency)  $924   $1,983 

 

The accompanying notes are an integral part of the interim consolidated financial statements.

 

 - 5 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

U.S. dollars in thousands (except share and per share data)

 

  

Nine months ended

September 30,

  

Three months ended

September 30,

 
   2016   2015   2016   2015 
   Unaudited   Unaudited 
                 
Revenues  $180   $108   $61   $40 
                     
Cost of revenues   77    35    27    10 
                     
Gross profit   103    73    34    30 
                     
Operating expenses:                    
                     
Research and development   447    297    161    87 
                     
Selling and marketing   390    207    120    73 
                     
General and administrative   741    533    298    208 
                     
Total operating expenses   1,578    1,037    579    368 
                     
Operating loss   1,475    964    545    338 
                     
Financial expense, net   208    1,112    52    683 
                     
Loss before taxes on income   1,683    2,076    597    1,021 
                     
Taxes on income   28    27    9    18 
                     
Net loss  $1,711   $2,103   $606   $1,039 
                     
Total comprehensive loss  $1,711   $2,103   $606   $1,039 
                     
Common stock and Preferred C stock basic and diluted net loss per share (Note 6)  $(0.37)  $(0.66)  $(0.13)  $(0.23)
                     
Weighted average number of shares of Common stock and Preferred C stock used in computing basic and diluted net loss per share (Note 6)   4,576,616    3,189,236    4,582,290    4,562,589 

 

The accompanying notes are an integral part of the interim consolidated financial statements.

 

 - 6 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)

U.S. dollars in thousands (except share data)

 

   Preferred stock   Common stock   Additional
paid-in
   Accumulated   Total
stockholders'
equity
 
   Number   Amount   Number   Amount   capital   deficit   (deficiency) 
                             
Balance as of January 1, 2015 (audited)   394,232    *)    163,580    *)    11,234    (16,850)   (5,616)
                                    
Issuance of Common stock, net of issuance costs   -    -    216,667    *)    511    -    511 
Issuance of Preferred C stock, net of issuance costs   833,333    *)    -    -    1,964    -    1,964 
Issuance of warrants to Common stock   -    -    -    -    446    -    446 
Conversion of Promissory Notes into Preferred B-1 stock and Preferred C stock   683,651    1    -    -    1,358    -    1,359 
Conversion of Promissory Notes into Preferred B-2 stock and Preferred C stock   1,508,001    2    -    -    2,099    -    2,101 
Conversion of Preferred A-1, A-2, B-1 and B-2 stock into Common stock   (2,128,868)   (2)   2,131,081    2    -    -    - 
Conversion of Convertible Promissory Notes into Preferred C stock   603,769    1    -    -    1,605    -    1,606 
Issuance of warrants to consultant   -    -    -    -    84    -    84 
Issuance of Preferred C stock to a consultant   57,143    *)    -    -    *)    -    *) 
Issuance of Common stock to a consultant   -    -    100,000    *)    *)    -    - 
Stock-based compensation related to options granted to consultants and employees   -    -    -    -    220    -    220 
Total comprehensive loss   -    -    -    -    -    (2,884)   (2,884)
                                    
Balance as of December 31, 2015 (audited)   1,951,261   $2    2,611,328   $2   $19,521   $(19,734)  $(209)
Issuance of Restricted stocks to consultant             9,000    *)    -    -    - 
Issuance of Common stocks upon exercise of options   -    -    12,382    *)    33    -    33 
Stock-based compensation   -    -    -    -    284    -    284 
Total comprehensive loss   -    -    -    -    -    (1,711)   (1,711)
                                    
Balance as of September 30, 2016 (unaudited)   1,951,261   $2    2,632,710   $2   $19,838   $(21,445)  $(1,603)

 

*)Represents amount less than $1.

  

The accompanying notes are an integral part of the interim consolidated financial statements.

 

 - 7 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

  

  

Nine months ended

September 30,

 
   2016   2015 
   Unaudited 
Cash flows from operating activities:          
           
Net loss  $(1,711)  $(2,103)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   6    7 
Stock-based compensation   284    153 
Benefit component of Promissory Notes   -    384 
Valuation of warrants to purchase Common stock   191    652 
Decrease (increase) in trade receivables   (6)   15 
Increase (decrease) in prepaid expenses and other accounts receivable   15    (58)
Decrease (increase) in inventories   8    (39)
Increase (decrease) in accounts payable   11    (62)
Increase (decrease) in other accounts payable   95    (113)
Decrease in accrued severance pay, net   -    (1)
Accrued interest on Promissory Notes   -    65 
           
Net cash used in operating activities   (1,107)   (1,100)
           
Cash flows from investment activities:          
Purchase of property and equipment   (8)   (1)
           
Net cash used in investment activities   (8)   (1)
           
Cash flows from financing activities:          
Proceeds from issuance of Common stock, Preferred stock and warrants, net of issuance costs   -    3,005 
Proceeds from exercise of options   33    - 
           
Net cash provided by financing activities   33    3,005 
           
Increase (decrease) in cash and cash equivalents   (1,082)   1,904 
Cash and cash equivalents at the beginning of the period   1,614    90 
           
Cash and cash equivalents at the end of the period  $532   $1,994 
           
Supplemental information and disclosure of non-cash financing transactions:          
           
Conversion of Promissory Notes into Preferred B-1, B-2 stock and Preferred C stock  $-   $5,066 

 

The accompanying notes are an integral part of the interim consolidated financial statements.

 

 - 8 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

 

NOTE 1:-GENERAL

 

a.NanoVibronix, Inc. ("the Company"), a U.S. (Delaware) corporation, commenced operations on October 20, 2003 and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.

 

The Company's principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.

  

  b. The Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the receipt of additional financing until profitability is achieved. The Company has incurred losses in the amount of $1,711 during the nine month period ended September 30, 2016, has an accumulated deficit of $21,445 as of September 30, 2016 and has accumulated negative cash flow from operating activities amounted to $1,107 for the nine month period ended September 30, 2016. The Company expects to continue incurring losses and negative flows from operations. As a result, the Company will not have sufficient resources to fund its operations for the next twelve months. These conditions raise substantial doubts about the Company’s ability to continue as a going concern. During the next twelve months management expects that the Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as its products do not reach commercial profitability. Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it will need to reduce activities, curtail or cease operations. The financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might be necessary should the Company be unable to continue as a going concern.

 

  c. In the opinion of management, the accompanying unaudited consolidated interim financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position and results of operations of the Company. These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2015, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2016. The balance sheet for December 31, 2015 was derived from the Company’s audited financial statements for the year ended December 31, 2015. The results of operations for the nine and three months ended September 30, 2016 are not necessarily indicative of results that could be expected for the entire fiscal year.

 

  d. On February 9, 2015, the Company filed a Registration Statement on Form 10 under the Securities Exchange Act of 1934, as amended, to register its Common stock under Section 12(g) of that act. The Form 10 was effective on April 10, 2015.

  

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

 

The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2015 are applied consistently in these financial statements.

 

Recent accounting pronouncements:

 

In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update change the accounting for certain stock-based compensation transactions, including the income tax consequences and cash flow classification for applicable transactions. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently evaluating the impact that this amendment will have on its consolidated financial statements.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. ASU 2016-13 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the impact of the adoption of this ASU on its consolidated financial statements.

 

NOTE 3:-UNAUDITED INTERIM FINANCIAL STATEMENTS

 

The accompanying unaudited consolidated financial statements as of September 30, 2016 have been prepared in accordance with the U.S. generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s consolidated financial position as of September 30, 2016 and the Company’s consolidated results of operation and the consolidated cash flows for the nine and three months ended September 30, 2016.

 

NOTE 4:-FAIR VALUE MEASUREMENTS

 

ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"), defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.

 

 - 9 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

 

ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. ASC 820 establishes three levels of inputs that may be used to measure fair value.

 

  Level 1 - quoted prices in active markets for identical assets or liabilities;

 

  Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

 

  Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

During February 2013, the Company signed a convertible Promissory Notes agreement (the “Agreement”) pursuant to which the Company issued secured convertible Promissory Notes (the “Notes”) to certain investors on February 5, 2013.  On each of March 28, 2013, June 3, 2013, August 5, 2013, October 7, 2013, December 9, 2013, February 6, 2014, April 1, 2014, May 15, 2014, June 16, 2014, August 7, 2014, September 7, 2014, October 13, 2014, November 19, 2014 and December 11, 2014, the Agreement and the Notes were amended and restated to increase the principal amount by $100.  In addition, with each amendment, the Company issued to the holders of the Note warrants to purchase up to 37,594 shares of common stock in consideration for an additional $100 per amendment. The exercise price at which the warrants may be exercised is $2.66 per share, subject to adjustment for stock splits, fundamental transactions or similar events including "down round" protection. The warrants expire within a period of five years, based on the issuance date. 

 

 

In April 2015, the holders of the Notes elected to convert the outstanding principal and interest thereunder into shares of the Company’s series C preferred stock. On that date, an aggregate principal balance of $1,500 and $106 in accrued interest were converted into 603,769 shares of series C preferred stock.  The shares of series C preferred stock were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold pursuant to the exemption from registration under the Securities Act of 1933, as amended, provided by Section 3(a)(9) of the Securities Act of 1933, as amended.

 

The Company measures the warrants at fair value by applying the Black-Scholes option pricing model in each reporting period until they are exercised or expired, with changes in fair value being recognized in the Company’s consolidated statement of comprehensive loss as financial income or expense.

 

 - 10 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

 

In estimating the warrants' fair value, the Company used the following assumptions:

 

   September 30,
   2016
    
Dividend yield (1)  0%
Expected volatility (2)  64.1-64.4%
Risk-free interest (3)  0.73%-0.85%
Expected term (years) (4)  1.1-3.0

 

  (1) Dividend yield - was based on the fact that the Company has not paid dividends to its stockholders in the past and does not expect to pay dividends to its stockholders in the future.
  (2) Expected volatility - was calculated based on actual historical stock price movements of companies in the same industry over a term that is equivalent to the expected term of the warrants.
  (3) Risk-free interest – was based on yield rate of non-index linked U.S. Federal Reserve treasury stock.
  (4) Expected term - was based on the maturity date of the warrants.

 

Fair value measurement using significant unobservable inputs (Level 3):

 

   Fair value of
warrants
to Common stock
 
     
Balance at January 1, 2016  $1,696 
Change in fair value of warrants   191 
      
Balance at September 30, 2016  $1,887 

 

In addition, the Company’s financial instruments also include cash and cash equivalents, trade receivables, prepaid expenses and other accounts receivable, accounts payable and other accounts payable. The fair value of these financial instruments was not materially different from their carrying values as of September 30, 2016 due to the short-term maturities of such instruments.

 

NOTE 5:-STOCKHOLDERS' EQUITY (DEFICIENCY)

 

a)Issuance of restricted shares

 

On July 18, 2016, the Company issued 9,000 restricted shares of Common stock, vesting over three months, to a consultant as part of the total consideration for its services.

 

b)Stock based compensation

 

During the nine-month period ended September 30, 2016, the Company's Board of Directors granted 100,000 options to purchase ordinary shares of the Company to its directors. The exercise price for such options is $5.35 per share, with vesting to occur over 1 year.

 

The following table presents the assumptions used to estimate the fair values of the options granted in the periods presented:

 

   Nine months ended
September 30,
 
   2016   2015 
   Unaudited 
         
Volatility   63.80%   65.3-66.8%
Risk-free interest rate   1.21%   1.44-1.61%
Dividend yield   0%   0%
Expected life (years)   5.5    5.5-6.5 

 

Weighted average fair value of options granted during the nine- month period ended September 30, 2016 and 2015 were $ 3.08 and $ 1.50, respectively.

 

During the nine-month period ended September 30, 2016 and 2015, the Company recorded share based compensation in a total amount of $240 and $153, respectively.

 

As of September 30, 2016, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $565, which is expected to be recognized over a weighted average period of approximately 1.17 years.

 

NOTE 6:-COMMITMENTS AND CONTINGENT LIABILITIES

 

a.The Company leases office facilities and motor vehicles under operating leases, which expire on various dates, the latest of which is 2017.

 

Future minimum lease commitments under non-cancelable operating lease agreements as of September 30, 2016 are as follows:

 

Year ended December 31,  Operating leases 
     
2016  $8 
2017   16 
      
Total  $24 

 

The Company leases motor vehicles under cancelable lease agreements. The Company has an option to be released from this lease agreement, which may result in penalties in a maximum amount of approximately $7.

 

Rent and related expenses were $22 and $23 for the nine months, and $7 and $8 for the three months ended September 30, 2016 and 2015, respectively.

 

Motor vehicle leases, and related expenses were $12 and $12 for the nine months, and $7 and $1 for the three months ended September 30, 2016 and 2015, respectively.

 

 - 11 - 

 

 

NANOVIBRONIX, INC. AND ITS SUBSIDIARY

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

 

b.Royalties to the Office of the Chief Scientist ("the OCS"):

 

Under the Company's subsidiary research and development agreements with the OCS and pursuant to applicable laws, the Company is required to pay royalties at the rate of 3-3.5% of sales of products developed with funds provided by the OCS, up to an amount equal to 100% of the OCS research and development grants received, linked to the dollar including accrued interest at the LIBOR rate. The Company is obligated to repay the Israeli Government for the grants received only to the extent that there are sales of the funded products.

 

As of September 30, 2016, the Company has a contingent obligation to pay royalties in the principal amount of approximately $478. In addition, the OCS may impose certain conditions on any arrangement under which it permits the Company to transfer technology or development out of Israel.

 

NOTE 7:-LOSS PER SHARE

 

All outstanding share options and warrants for the nine months and three months ended September 30, 2016 and for the nine months and three months ended September 30, 2015 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented.

 

Retrospective adjustment of net loss per share information

 

The Company has shares of Series C Preferred Stock outstanding which were issued in early 2015. The specific terms and conditions of the Series C Preferred Shares are disclosed in Note 10 to the Company’s December 31, 2015 audited consolidated financial statements which should be read along with these unaudited interim consolidated financial statements.

 

When preparing its consolidated financial statements for the year ended December 31, 2015, its interim consolidated financial statements for the respective quarters and year to date periods contained during 2015, and also the interim consolidated financial statements for the quarter ended March 31, 2016, the Company considered these convertible security to be a common stock equivalents but excluded them from its dilutive earnings (loss) per share computation as it concluded that the securities would be anti-dilutive in nature if or when converted. However, upon further analysis and when preparing it interim consolidated financial statements for the second quarter of 2016, the Company has concluded that these securities participate equally with common shares in the profits, losses and liquidation values of the Company, and while limited in voting they can be readily converted into voting common shares at any time. The Company has concluded that they are participating securities that should have been included as a component of both basic and dilutive earnings (loss) per share for all periods previously presented. Adjusted figures are presented below to reflect this revised conclusion.

 

   Quarter
ended
March 31,
2015
   Quarter
ended
June 30,
2015
   Six months
ended
June 30,
2015
   Quarter
ended
September
30, 2015
   Nine months
ended
September
30, 2015
   Year ended
December
31, 2015
   Quarter
ended
March 31,
2016
 
                             
Net loss   630    434    1,064    1,039    2,103    2,884    495 
                                    
Weighted average common shares as previously reported   281,543    2,388,220    1,336,085    2,611,328    1,767,417    1,978,395    2,621,191 
                                    
Weighted average Series C Preferred shares outstanding   460,127    1,839,468    1,151,216    1,951,261    1,421,819    1,557,953    1,951,261 
                                    
Basic and dilutive weighted average shares outstanding, as adjusted   741,670    4,227,688    2,487,301    4,562,589    3,189,236    3,536,348    4,572,452 
                                    
Basic and dilutive loss per share, as adjusted   (0.85   (0.10   (0.43)   (0.23)    (0.66)    (0.82)    (0.11) 

 

The Company has retrospectively adjusted for the foregoing matter in the accompanying interim consolidated financial statements for the nine month periods ended September 30, 2016 and 2015.

 

NOTE 8:-GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA

 

Summary information about geographic areas:

 

The Company manages its business on the basis of one reportable segment, and derives revenues from selling its products directly to patients as well as through distributor agreements. The following is a summary of revenues within geographic areas:

 

  

Nine months ended

September 30,

  

Three months ended

September 30,

 
   2016   2015   2016   2015 
                 
United States  $ 62   $ 41   $ 26   $ 11 
Europe   44    15    6    7 
Israel   11    10    4    5 
India   24    7    15    - 
Rest of the world   39    35    10    17 
                     
   $180   $108   $61   $40 

 

During the nine and three month period ended September 30, 2016, revenues from distributors accounted for 34% and 36% of total revenues. During the nine and three month period ended September 30, 2015, revenues from distributors accounted for 27% and 32% of total revenues.

 

The Company's long-lived assets are all located in Israel.  

 

NOTE 9:-SUBSEQUENT EVENTS

 

The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. For its interim consolidated financial statements as of September 30, 2016 (unaudited), and for the three months period then ended (unaudited), the Company evaluated subsequent events through November 14, 2016, the date that the consolidated financial statements were issued.

 

On October 13, 2016, the Board of Directors of the Company (the “Board”) appointed Brian M. Murphy as a director and chief executive officer of the Company. In connection with Mr. Murphy’s appointment as the chief executive officer, the Company entered into an employment agreement, dated October 13, 2016, with Mr. Murphy (the “Employment Agreement”). Pursuant to the Employment Agreement, Mr. Murphy is entitled to (i) an annual salary of $181, which shall automatically increase to (a) $200, effective as of January 1 of the year immediately following any calendar year during which the Company generates gross sales exceeding $1,000, and (b) $225, effective as of January 1 of the year immediately following any calendar year during which the Company generates gross sales exceeding $2,000; (ii) an annual performance bonus up to (a) $150 in the aggregate, up to $100 of which will be based on Mr. Murphy meeting the performance criteria for the year and up to $50 of which will be based on the Board’s sole discretion in 2017, or (b) $100 based on Mr. Murphy meeting the performance criteria for the year, as determined in good faith by the Board, in 2018 and all subsequent years; and (iii) a one-time bonus of $75 if the Company completes a financing or series of financings that cause the Company’s Common Stock to be listed on a registered national securities exchange within six months from October 13, 2016.

 

On October 14, 2016, the Board appointed Christopher M. Fashek as a director of the Company and chairman of the Board. Pursuant to the offer letter, Mr. Fashek will receive as compensation $100 per year, payable in regular semi-monthly installments. In addition, Mr. Fashek will receive an additional one-time bonus payment of $25 if the Company’s Common Stock becomes listed on a registered national securities exchange within six months from October 14, 2016, provided that Mr. Fashek is serving as chairman of the Board at the time of such listing. Mr. Fashek was also granted, outside of the NanoVibronix, Inc. 2014 Long Term Incentive Plan, a stock option to purchase 91,679 shares of the Company’s common stock vesting over four years.

 

 - 12 - 

 

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

   

You should read the following discussion and analysis of financial condition and results of operations in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q.

 

Unless the context requires otherwise, references in this Form 10-Q to the “Company,” “NanoVibronix,” “we,” “our” and “us” refer to NanoVibronix, Inc., a Delaware corporation, and its subsidiaries.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements,” which include information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

 

  · The timing of clinical studies and eventual U.S. Food and Drug Administration approval of WoundShield™ and our other product candidates.

 

  · Regulatory actions that could adversely affect the price of or demand for our approved products.

 

  · Market acceptance of existing and new products.

 

  · Favorable or unfavorable decisions about our products from government regulators, insurance companies or other third-party payers.

 

  · Our intellectual property portfolio.

 

  · Our ability to recruit and retain qualified regulatory and research and development personnel.

 

  · Unforeseen changes in healthcare reimbursement for any of our approved products.

 

  · Lack of financial resources to adequately support our operations.

 

  · Difficulties in maintaining commercial scale manufacturing capacity and capability.

 

  · Our ability to generate internal growth.

 

  · Changes in our relationship with key collaborators.

 

  · Changes in the market valuation or earnings of our competitors or companies viewed as similar to us.

 

  · Our failure to comply with regulatory guidelines.

 

  · Uncertainty in industry demand and patient wellness behavior.

 

  · General economic conditions and market conditions in the medical device industry.

 

  · Future sales of large blocks of our common stock, which may adversely impact our stock price.

 

  · Depth of the trading market in our common stock.

  

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. For a discussion of these and other risks that relate to our business and financial performance, you should carefully review the risks and uncertainties described under the heading “Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and those described from time to time in our future reports filed with the Securities and Exchange Commission. Moreover, new risks regularly emerge and it is not possible for us to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this Form 10-Q are based on information available to us on the date of this prospectus. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 - 13 - 

 

 

Overview

 

We are a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals. Our WoundShield, PainShield® and UroShield® products are backed by novel technology which relates to ultrasound delivery through surface acoustic waves.

 

Critical Accounting Policies

 

A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are more fully described in Note 2 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. There have not been any material changes to such critical accounting policies since December 31, 2015.

 

The currency of the primary economic environment in which our operations are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, our functional currency is the dollar.

 

Results of Operations

 

Nine months Ended September 30, 2016 Compared to Nine months Ended September 30, 2015

 

Revenues. For the nine months ended September 30, 2016 and 2015, our revenues were approximately $180,000 and $108,000, respectively, an increase of approximately 67%, or $72,000, between the periods. The increase was mainly attributable to increased sales from adding distributors as well as having positive results from our increased marketing campaigns. Our revenues may fluctuate as we add new customers or when existing customers make large purchases of our products during one period and no purchases during another period. Our revenues may fluctuate from quarter-to-quarter and, as we continue to grow our business, growth in revenues by quarter may not be linear or consistent.

 

 - 14 - 

 

 

For the nine months ended September 30, 2016, the percentage of revenues attributable to our products was: PainShield - 89% and UroShield - 11%. For the nine months ended September 30, 2015, the percentage of revenues attributable to our products was: PainShield - 94% and UroShield - 6%. For the nine months ended September 30, 2016 and 2015, the percentage of revenues attributable to the disposable units of our PainShield and UroShield products was 45% and 41%, respectively. For the nine months ended September 30, 2016 and 2015, the portion of our revenues that was derived from distributors was 34% and 27%, respectively.

 

Gross Profit. For the nine months ended September 30, 2016, gross profit increased by approximately 41%, or $30,000, to approximately $103,000 from approximately $73,000 during the same period in 2015. The increase was due to the increase in revenues.

 

Gross profit as a percentage of revenues was approximately 57% and 68% for the nine months ended September 30, 2016 and 2015, respectively. The decrease in gross profit as a percentage is mainly due to the increased percentage of distributor sales which typically carry a lower gross profit percentage than our direct to consumer sales.

 

Research and Development Expenses. For the nine months ended September 30, 2016 and 2015, research and development expenses were approximately $447,000 and $297,000, respectively, an increase of approximately 51%, or $150,000, between the periods. This increase was mainly due to an increased volume of clinical trial costs that took place in 2016 as well as increased development of new products.

 

Our research and development expenses consist mainly of payroll expenses to employees involved in research and development activities, stock-based compensation expenses, expenses related to subcontracting, patents application and registration, clinical trial and facilities expenses associated with and allocated to research and development activities.

 

Research and development expenses as a percentage of total revenues were approximately 248% and 275% for the nine months ended September 30, 2016 and 2015, respectively. The decrease was due primarily to the increase in revenues which was offset by the increased activity described above.

 

Selling and Marketing Expenses. For the nine months ended September 30, 2016 and 2015, selling and marketing expenses were approximately $390,000 and $207,000, respectively, an increase of approximately 88%, or $183,000, between the periods. The increase was mainly due to an increase in selling and marketing activities, particularly increased trade show expenses as well as a favorable debt settlement which reduced costs by $75,000 in 2015.

 

Selling and marketing expenses as a percentage of total revenues were approximately 217% and 192% for the nine months ended September 30, 2016 and 2015, respectively. The increase was due primarily to the increase in revenues and the increase in trade show expenses described above.

 

General and Administrative Expenses For the nine months ended September 30, 2016 and 2015, general and administrative expenses were approximately $741,000 and $533,000, respectively, an increase of approximately 39%, or $208,000, between the periods. The increase was mainly due to the costs and increased professional fees associated with our becoming a public company.

 

Our general and administrative expenses consist mainly of payroll expenses for management and administrative employees, share-based compensation expenses, accounting, legal and facilities expenses associated with general and administrative activities.

 

Financial Expenses net. For the nine months ended September 30, 2016 and 2015, financial expenses, net were approximately $209,000 and $1,112,000, respectively, a decrease of approximately 81%, or $904,000, between the periods. The decrease resulted primarily from the lower valuation adjustment of our warrants that were issued with our 2013 and 2015 convertible promissory notes.

 

Tax expenses. For the nine months ended September 30, 2016 and 2015, tax expenses were $28,000 and $27,000, respectively. The tax expense is computed by multiplying income before taxes at our Israeli subsidiary by the appropriate tax rate.

 

Net Loss. Our net loss decreased by approximately $392,000, or 18%, to approximately $1,711,000 for the nine months ended September 30, 2016 from approximately $2,103,000 in the same period of 2015. The increase in net loss resulted primarily from the factors described above.

 

 - 15 - 

 

 

Three Months Ended September 30, 2016 Compared to Three Months Ended September 30, 2015

 

Revenues. For the three months ended September 30, 2016 and 2015, our revenues were approximately $61,000 and $40,000, respectively, an increase of approximately 53%, or $21,000, between the periods. The increase was mainly attributable to increased sales from adding distributors as well as having positive results from our increased marketing campaigns. Our revenues may fluctuate as we add new customers or when existing customers make large purchases of our products during one period and no purchases during another period. Our revenues may fluctuate from quarter-to-quarter and, as we continue to grow our business, growth in revenues by quarter may not be linear or consistent.

 

For the three months ended September 30, 2016, the percentage of revenues attributable to our products was: PainShield - 82% and UroShield - 18%. For the three months ended September 30, 2015, the percentage of revenues attributable to our products was: PainShield - 98% and UroShield - 2%. For the three months ended September 30, 2016 and 2015, the percentage of revenues attributable to the disposable units of our PainShield and UroShield products was 38% and 45%, respectively. For the three months ended September 30, 2016 and 2015, the portion of our revenues that was derived from distributors was 36% and 32%, respectively.

 

Gross Profit. For the three months ended September 30, 2016, gross profit increased by approximately 13%, or $4,000, to approximately $34,000 from approximately $30,000 during the same period in 2015. The increase was due to the increase in revenues.

 

Gross profit as a percentage of revenues was approximately 56% and 75% for the three months September 30, 2016 and 2015, respectively. The decrease in gross profit as a percentage is mainly due to the increased percentage of distributor sales which typically carry a lower gross profit percentage than our direct to consumer sales. 

 

Research and Development Expenses. For the three months ended September 30, 2016 and 2015, research and development expenses were approximately $161,000 and $87,000, respectively, an increase of approximately 85%, or $74,000, between the periods. The decrease in gross profit as a percentage is mainly due to the increased percentage of distributor sales which typically carry a lower gross profit percentage than our direct to consumer sales.

 

Our research and development expenses consist mainly of payroll expenses to employees involved in research and development activities, stock-based compensation expenses, expenses related to subcontracting, patents application and registration, clinical trial and facilities expenses associated with and allocated to research and development activities.

 

Research and development expenses as a percentage of total revenues were approximately 264% and 218% for the three months ended September 30, 2016 and 2015, respectively. The increase was primarily due to the increase in expenses related to our clinical trials.

 

 - 16 - 

 

 

Selling and Marketing Expenses. For the three months ended September 30, 2016 and 2015, selling and marketing expenses were approximately $119,000 and $73,000, respectively, an increase of approximately 63%, or $46,000, between the periods. The increase was mainly due to an increase in selling and marketing activities, particularly increased salaries and marketing expenses.

 

Selling and marketing expenses as a percentage of total revenues were approximately 197% and 183% for the three months ended September 30, 2016 and 2015, respectively. The increase was due primarily to the increase in revenues.

 

Selling and marketing expenses consist mainly of payroll expenses to direct sales and marketing employees, stock-based compensation expenses, travel expenses, advertising and marketing expenses, rent and facilities expenses associated with and allocated to selling and marketing activities.

 

General and Administrative Expenses. For the three months ended September 30, 2016 and 2015, general and administrative expenses were approximately $298,000 and $208,000, respectively, an increase of approximately 43%, or $90,000, between the periods. The increase was mainly due to the costs and increased professional fees associated with our becoming a public company.

 

Our general and administrative expenses consist mainly of payroll expenses for management and administrative employees, share-based compensation expenses, accounting, legal and facilities expenses associated with general and administrative activities.

 

Financial Expenses, net. For the three months ended September 30, 2016 and 2015, net were approximately $52,000 and $683,000, respectively, a decrease of approximately 92%, or $631,000, between the periods. The decrease resulted primarily from the higher valuation adjustment of our warrants that were issued with our 2013 and 2015 convertible promissory notes.

 

Tax expenses. For the three months ended September 30, 2016 and 2015, tax expenses were $9,000 and $18,000, respectively. The tax expenses are attributed to our Israel subsidiary.

 

Net Loss. Our net loss decreased by approximately $432,000, or 42%, to approximately $607,000 for the three months ended September 30, 2016 from approximately $1,039,000 in the same period of 2015. The decrease in net loss resulted primarily from the factors described above.

 

 - 17 - 

 

 

Liquidity and Capital Resources

 

We continue to incur losses and negative cash flows from operating activities. We have incurred losses in the amount of $1,711,000 during the nine month period ended September 30, 2016, and have accumulated negative cash flow from operating activities of $1,107,000 for the nine month period ended September 30, 2016. We expect to continue to incur losses and negative cash flows from operating activities and as a result, we will not have sufficient resources to fund our operation for the next twelve months. These conditions raise doubts about our ability to continue as a going concern. During the next twelve months management expects that the Company will need to raise additional capital to finance its losses and negative cash flows from operations for the next twelve months and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.

 

During the nine months ended September 30, 2016, and through November 14, 2016, we met our short-term liquidity requirements from our existing cash reserves. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products, our development of future products and competing technological and market developments. We intend to continue to use our existing cash reserves use to meet our short-term liquidity requirements as well as to advance our long-term plans. It is our current belief that if we do not continue to see significant increases in revenues, or if we are unable to raise additional capital at a later time in the current year, we will need to reduce our operating budget as well as sales and marketing expenses which may impair our ability to execute our business objectives. It should also be noted that there are no assurances that we would be able to raise additional capital on terms favorable to us.

  

Nine months Ended September 30, 2016 Compared to nine months Ended September 30, 2015

 

General. As of September 30, 2016, we had cash and cash equivalents of approximately $532,000, compared to approximately $1,614,000 as of December 31, 2015. The decrease is attributable primarily to our net cash used in operating activities. We have historically met our cash needs through a combination of issuance of equity, borrowing activities and sales. Our cash requirements are generally for product development, research and development cost, marketing and sales activities, finance and administrative cost, capital expenditures and general working capital.

 

Cash used in our operating activities was approximately $1,107,000 for the nine months ended September 30, 2016 and $1,100,000 for the same period in 2015.

 

Cash used in investing activities was $8,000 and $1,000 for the nine month periods ended September 30, 2016 and 2015, respectively, and was related to purchases of fixed assets.

 

Cash provided by financing activities was approximately $33,000 for the nine months ended September 30, 2016 derived from proceeds received on the exercise of options and $3,005,000 for the nine months ended September 30, 2015, which derived from issuance of shares of common stock, series C preferred stock and warrants to purchase shares of common stock for aggregate consideration of $3,005,000, which is net of issuance costs of $145,000.

 

Off Balance Sheet Arrangements

 

As of September 30, 2016, we have no off-balance sheet transactions, arrangements, obligations (including contingent obligations), or other relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

 - 18 - 

 

 

Factors That May Affect Future Operations

 

We believe that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors, including the ordering patterns of our distributors, timing of regulatory approvals, the implementation of various phases of our clinical trials and manufacturing efficiencies due to the learning curve of utilizing new materials and equipment. Our operating results could also be impacted by a weakening of the Euro and strengthening of the New Israeli Shekel, or NIS, both against the U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursement policies pertaining to our products.

 

Item 3.Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

  (a) Evaluation of Disclosure Controls and Procedures. As of September 30, 2016, we conducted an evaluation, under the supervision and participation of management including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

 

Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of September 30, 2016.

  

  (b) Changes in Internal Controls. There have been no changes in the Company’s internal control over financial reporting that occurred during the nine months ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Part II – OTHER INFORMATION

 

Item 1.Legal Proceedings

 

From time to time, we may be involved in litigation that arises through the normal course of business. As of the date of this filing, we are not a party to any material litigation nor are we aware of any such threatened or pending litigation.

 

There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock, or any associate of any of the foregoing is an adverse party or has a material interest adverse to our interest.

 

Item 1A.Risk Factors

 

During the fiscal quarter ended September 30, 2016, there were no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 30, 2016.

 

 - 19 - 

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

In July 2016, we issued 9,000 restricted shares of common stock to Emerging Markets Consulting, LLC, a consultant to us, as consideration for consulting services. These securities were not registered under the Securities Act of 1933, as amended, or the securities laws of any state, and were offered and sold pursuant to the exemption from registration under the Securities Act of 1933, as amended, provided by Section 4(2) of the Securities Act of 1933, as amended. The investor was an accredited investor (as defined by Rule 501 under the Securities Act of 1933, as amended) at the time of the transaction.

 

Item 3. Defaults Upon Senior Securities

 

Not applicable.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

See Index to Exhibits.

 

 - 20 - 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NANOVIBRONIX, INC.
     
Date: November 14, 2016 By: /s/ Brian M. Murphy
    Name: Brian M. Murphy.
    Title: Chief Executive Officer
     
 Date: November 14, 2016 By: /s/ Stephen Brown
    Name: Stephen Brown
    Title: Chief Financial Officer

 

 - 21 - 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
3.1   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2016)
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2015)
10.1   Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 10.28 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2015).
10.2   Offer Letter, dated October 14, 2016, between NanoVibronix, Inc. and Christopher M. Fashek (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)
10.3   Nonqualified Stock Option Agreement, dated October 14, 2016, between NanoVibronix, Inc. and Christopher M. Fashek (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)
10.4   Employment Agreement, dated October 13, 2016, between NanoVibronix, Inc. and Brian Murphy (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*   The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, formatted in XBRL (eXtensible Business Reporting Language), (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Changes in Equity (Deficiency) (iv) Consolidated Statements of Cash Flows and (v) the Notes to the Consolidated Financial Statements

 

* Filed herewith.  

 

 - 22 -